Windlas Biotech Ltd - 543329 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of Conference Call to discuss financial performance for quarter and financial year ended March 31, 2022 (Revised)06-05-2022
06-05-2022
Windlas Biotech Ltd - 543329 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of Conference Call to discuss financial performance for quarter and financial year ended March 31, 2022.06-05-2022
Windlas Biotech Ltd - 543329 - Board to consider Dividend
Windlas Biotech Ltd has informed BSE that a meeting of the Board of Directors of the Company is scheduled to be held on May 12, 2022, inter alia, to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2022 and to consider recommendation of dividend, if any, amongst other routine matters.Also advised that in accordance with Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons of the Company pursuant to the SEBI (Prohibition of Insider Trading) Regulations 2015, the Trading Window of the Company is already closed from April 01, 2022, vide the Company''s letter dated March 31, 2022, and it shall reopen on May 15, 2022.05-05-2022
Windlas Biotech Ltd - 543329 - Board Meeting Intimation for Approval Of Audited Standalone And Consolidated Financial Results For The Quarter And Year Ended March 31, 2022
Windlas Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/05/2022 ,inter alia, to consider and approve To consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2022 and to consider recommendation of dividend, if any, amongst other routine matters.05-05-2022
Windlas Biotech Ltd - 543329 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for ICICI Prudential Mutual Fund21-04-2022
Windlas Biotech Ltd - 543329 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Company received certificate of Good Manufacturing Practices (GMP) from SAHPRA (South African Health Products Regulatory Authority)16-04-2022
Windlas Biotech Ltd - 543329 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
European Union GMP Inspection14-04-2022
Windlas Biotech Ltd - 543329 - Compliance Certificate In Terms Of Regulation 40 (9) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Year Ended On March 31, 2022.
Compliance Certificate in terms of Regulation 40 (9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended on March 31, 2022.09-04-2022
Windlas Biotech Ltd - 543329 - Compliance Certificate Under Regulation 7(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Period Ended March 31, 2022.
Compliance Certificate under Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the period ended March 31, 2022.07-04-2022
Windlas Biotech Ltd - 543329 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74 (5) of the SEBl (Depositories and Participants) Regulations, 2018 for the Quarter ended March 31, 2022.07-04-2022